Effect of Dexmedetomidine for Postoperative Intravenous Patient Controlled Analgesia

W

Weifeng Tu

Status and phase

Unknown
Phase 4

Conditions

Patient-Controlled Analgesia

Treatments

Drug: Dexmedetomidine
Drug: Dezocine
Drug: Flubiprofen

Study type

Interventional

Funder types

Other

Identifiers

NCT03014713
Dexmedetomidine PCA

Details and patient eligibility

About

The purpose of this study is to explore the effectiveness of dexmedetomidine as an adjunctive analgesic, combined with dezocine and flubiprofen, used in intravenous Patient-Controlled Analgesia (PCA) after open colorectal surgery.

Full description

Dexmedetomidine is a selective alpha-2 adrenoceptor agonist, which has been demonstrated to have anaesthetic, sedative and analgesic-sparing effects. Besides, Dexmedetomidine has been reported to cause sedative effects and reduce opioid requirements in the perioperative period. Many studies had been conducted to reduce the side effect of opioid analgesic. The current trend of reducing opioid analgesic side effect is direct combination of other drugs in PCA. The advantages of this method are convenient in clinical use and preventive for side effects. In this study, 50 patients who is undergoing elective colorectal surgery will be randomly allocated into two groups (Control group and Dexmedetomidine group). Patients in both groups will be given a patient-controlled analgesia (PCA) pump in post anesthetic recovery unit (PACU) after surgery. The PCA protocol of Control group is dezocine 0.6mg/kg, flubiprofen 3mg/kg, diluted into 120ml and administer at a background infusion of 2ml/h, and a bolus of 2ml, with a lock-out of 15min. The PCA protocol of Dexmedetomidine group is dezocine 0.6mg/kg, flubiprofen 3mg/k and dexmedetomidine 6μg/kg diluted into 120ml and administer at a background infusion of 2ml/h, and a bolus of 2ml, with a lock-out of 15min.

Enrollment

50 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • American Society of Anesthesiologists(ASA) Ⅰ-Ⅱ patient undergoing open colorectal surgery
  • Written informed consent from the patient or the relatives of the participating patient.
  • BMI:18~30kg/m2

Exclusion criteria

  • Mental illness or cannot communicate.;
  • A second operation during the study;
  • Slow-type arrhythmias or hypotension;
  • Lung infection or sleep apnea syndrome;
  • Renal failure;
  • Alcohol or drug abuse;
  • Already taking gabapentin, pregabalin, benzodiazepin or antidepression drug;
  • Long-term use of analgesics,sedatives or non steroidal anti-inflammatory drugs history;

Trial design

50 participants in 2 patient groups

Control Group
Active Comparator group
Description:
Patients in this group receive intravenous Patient-Controlled Analgesia(PCA) pump after surgery.The intravenous PCA protocol is dezocine 0.01mg/kg/h,flubiprofen 0.05mg/kg/h.
Treatment:
Drug: Flubiprofen
Drug: Dezocine
Dexmedetomidine Group
Experimental group
Description:
Patients in this group receive intravenous Patient-Controlled Analgesia(PCA) pump after surgery.The intravenous PCA protocol is dezocine 0.01mg/kg/h,flubiprofen 0.05mg/kg/h,dexmedetomidine 0.1μg/kg/h.
Treatment:
Drug: Flubiprofen
Drug: Dezocine
Drug: Dexmedetomidine

Trial contacts and locations

0

Loading...

Central trial contact

Weifeng Tu, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems